Published February 16, 2016 | Version v1
Journal article Restricted

Comparison of Early-Phase 11C-Deuterium-L-Deprenyl and 11C-PiB PET for Assessing Brain Perfusion in Alzheimer's Disease.

  • 1. Division of Translational Alzheimer Neurobiology, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
  • 2. Division of Translational Alzheimer Neurobiology, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden; Department of Psychology, Stockholm University, Stockholm, Sweden and Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
  • 3. Department of Surgical Sciences, Section of Nuclear Medicine & PET, Uppsala University, Uppsala, Sweden
  • 4. Deparment of Chemistry, Uppsala University, Uppsala, Sweden
  • 5. Division of Translational Alzheimer Neurobiology, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden and Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden

Description

The PET tracer 11C-deuterium-L-deprenyl (11C-DED) has been used to visualize activated astrocytes in vivo in patients with Alzheimer's disease (AD). In this multitracer PET study, early-phase 11C-DED and 11C-Pittsburgh compound-B (11C-PiB) (eDED and ePiB, respectively) were compared as surrogate markers of brain perfusion, and the extent to which 11C-DED binding is influenced by brain perfusion was investigated.

METHODS: 11C-DED, 11C-PiB and 18F-fluorodeoxyglucose (FDG) dynamic PET scans were performed in age-matched groups comprising AD patients (n = 8), patients with mild cognitive impairment (MCI, n = 17), and healthy controls (HC, n = 16). A modified-reference Patlak model was used to quantify 11C-DED binding. A Simplified Reference Tissue Model was applied to both 11C-DED and 11C-PiB to measure brain perfusion relative to the cerebellar gray matter (GM) (R1) and binding potentials. 11C-PiB retention and 18F-FDG uptake were also quantified as target-to-pons standardized uptake value ratios in 12 regions of interest (ROIs).

RESULTS: The strongest within-subject correlations with the corresponding R1 values (R1,DED and R1,PiB, respectively) and with 18F-FDG uptake were obtained when the eDED and ePiB PET data were measured 1-4 min post-injection. The optimum eDED/ePiB intervals also showed strong, significant ROI-based inter-subject Pearson's correlations with R1,DED/R1,PiB and with 18F-FDG uptake, while 11C-DED binding was largely independent of brain perfusion, as measured by eDED. Corresponding voxelwise correlations confirmed the ROI-based results. Temporo-parietal eDED or ePiB brain perfusion measurements were highly discriminative between patient and control groups, with discriminative ability statistically comparable to that of temporo-parietal 18F-FDG glucose metabolism. Hypometabolism extended over wider regions than hypoperfusion in patient groups compared to controls.

CONCLUSION: The 1-4 min early-frame intervals of 11C-DED or 11C-PiB are suitable surrogate measures for brain perfusion. 11C-DED binding is independent of brain perfusion and thus 11C-DED PET can provide information on both functional (brain perfusion) and pathological (astrocytosis) aspects from a single PET scan. In comparison with glucose metabolism, early-phase 11C-DED and 11C-PiB perfusion appear to provide complementary rather than redundant information.

Files

Restricted

The record is publicly accessible, but files are restricted to users with access.

Additional details

Funding

INMIND – Imaging of Neuroinflammation in Neurodegenerative Diseases 278850
European Commission